European Radiology

, Volume 22, Issue 7, pp 1451–1464

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging

  • M. O. Leach
  • B. Morgan
  • P. S. Tofts
  • D. L. Buckley
  • W. Huang
  • M. A. Horsfield
  • T. L. Chenevert
  • D. J. Collins
  • A. Jackson
  • D. Lomas
  • B. Whitcher
  • L. Clarke
  • R. Plummer
  • I. Judson
  • R. Jones
  • R. Alonzi
  • T. Brunner
  • D. M. Koh
  • P. Murphy
  • J. C. Waterton
  • G. Parker
  • M. J. Graves
  • T. W. J. Scheenen
  • T. W. Redpath
  • M. Orton
  • G. Karczmar
  • H. Huisman
  • J. Barentsz
  • A. Padhani
  • on behalf of the Experimental Cancer Medicine Centres Imaging Network Steering Committee
Magnetic Resonance

DOI: 10.1007/s00330-012-2446-x

Cite this article as:
Leach, M.O., Morgan, B., Tofts, P.S. et al. Eur Radiol (2012) 22: 1451. doi:10.1007/s00330-012-2446-x

Abstract

Many therapeutic approaches to cancer affect the tumour vasculature, either indirectly or as a direct target. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has become an important means of investigating this action, both pre-clinically and in early stage clinical trials. For such trials, it is essential that the measurement process (i.e. image acquisition and analysis) can be performed effectively and with consistency among contributing centres. As the technique continues to develop in order to provide potential improvements in sensitivity and physiological relevance, there is considerable scope for between-centre variation in techniques. A workshop was convened by the Imaging Committee of the Experimental Cancer Medicine Centres (ECMC) to review the current status of DCE-MRI and to provide recommendations on how the technique can best be used for early stage trials. This review and the consequent recommendations are summarised here.

Key Points

Tumour vascular function is key to tumour development and treatment

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can assess tumour vascular function

Thus DCE-MRI with pharmacokinetic models can assess novel treatments

Many recent developments are advancing the accuracy of and information from DCE-MRI

Establishing common methodology across multiple centres is challenging and requires accepted guidelines

Keywords

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) Tumour vasculature Angiogenesis Cancer Early phase trials 

Copyright information

© European Society of Radiology 2012

Authors and Affiliations

  • M. O. Leach
    • 1
  • B. Morgan
    • 2
  • P. S. Tofts
    • 3
  • D. L. Buckley
    • 4
  • W. Huang
    • 5
  • M. A. Horsfield
    • 6
  • T. L. Chenevert
    • 7
  • D. J. Collins
    • 8
  • A. Jackson
    • 9
  • D. Lomas
    • 10
  • B. Whitcher
    • 11
  • L. Clarke
    • 12
  • R. Plummer
    • 13
  • I. Judson
    • 14
  • R. Jones
    • 15
  • R. Alonzi
    • 16
  • T. Brunner
    • 17
  • D. M. Koh
    • 18
  • P. Murphy
    • 19
  • J. C. Waterton
    • 20
  • G. Parker
    • 21
  • M. J. Graves
    • 22
  • T. W. J. Scheenen
    • 23
  • T. W. Redpath
    • 24
  • M. Orton
    • 1
  • G. Karczmar
    • 25
  • H. Huisman
    • 26
  • J. Barentsz
    • 27
  • A. Padhani
    • 28
  • on behalf of the Experimental Cancer Medicine Centres Imaging Network Steering Committee
  1. 1.Cancer Research UK and EPSRC Cancer Imaging CentreInstitute of Cancer Research & Royal Marsden NHS Foundation TrustSuttonUK
  2. 2.College of Medicine, Biological Sciences & PsychologyUniversity of LeicesterLeicesterUK
  3. 3.Clinical Imaging Sciences CentreBrighton and Sussex Medical School, University of SussexSussexUK
  4. 4.Division of Medical PhysicsUniversity of LeedsLeedsUK
  5. 5.Advanced Imaging Research CentreOregon Health & Science UniversityPortlandUSA
  6. 6.Department of Cardiovascular SciencesMedical Physics Section, Leicester Royal InfirmaryLeicesterUK
  7. 7.University of Michigan Health SystemAnn ArborUSA
  8. 8.Cancer Research UK and EPSRC Cancer Imaging CentreRoyal Marsden Hospital NHS Foundation TrustSuttonUK
  9. 9.University of Manchester, Wolfson Molecular Imaging CentreWithingtonUK
  10. 10.Department of RadiologyUniversity of CambridgeCambridgeUK
  11. 11.Mango SolutionsUnit 2 Greenways Business ParkChippenhamUK
  12. 12.Imaging Technology Development BranchCancer Imaging ProgramRockvilleUSA
  13. 13.Medical Oncology, Northern Institute for Cancer ResearchUniversity of Newcastle Upon Tyne, The Medical SchoolNewcastle Upon TyneUK
  14. 14.Royal Marsden HospitalSuttonUK
  15. 15.Beatson West of Scotland Cancer CentreGlasgowUK
  16. 16.Mount Vernon Cancer CentreNorthwoodUK
  17. 17.Gray Institute for Radiation, Oncology & BiologyOxfordUK
  18. 18.Diagnostic RadiologyRoyal Marsden NHS Foundation TrustSuttonUK
  19. 19.Clinical ImagingGlaxoSmithKlineLondonUK
  20. 20.AstraZenecaPersonalised Healthcare & BiomarkersMacclesfieldUK
  21. 21.Biomedical Imaging InstituteUniversity of ManchesterManchesterUK
  22. 22.Cambridge University Hospitals NHS Foundation TrustCambridgeUK
  23. 23.Department of RadiologyRadbound University Nijmegen Medical CenterNijmegenThe Netherlands
  24. 24.Aberdeen Biomedical Imaging CentreUniversity of AberdeenForesterhillUK
  25. 25.Department of Radiology, Lynn S Florsheim MRIS LabUniversity of ChicagoChicagoUSA
  26. 26.Radbound University Medical CenterNijmegenThe Netherlands
  27. 27.Department of RadiologyRadbound University Medical CentreNijmegenThe Netherlands
  28. 28.Paul Strickland Scanner CentreMount Vernon Cancer CentreNorthwoodUK

Personalised recommendations